Loading the comparison…
Loading the comparison…
Recovery & Repair
The 'Wolverine stack' in one vial: local and whole-body repair together.
Recovery & Repair
An EPO-derived peptide that protects tissue without raising red blood cells.
BPC-157 + TB-500 is not FDA-approved and rated 2/5 for evidence; ARA-290 is not FDA-approved and rated 3/5. ARA-290 has more human evidence behind it. Both are banned in sport by WADA. Both are used for recovery & repair goals.
| Compare | BPC-157 + TB-500 The 'Wolverine stack' in one vial: local and whole-body repair together. | ARA-290 An EPO-derived peptide that protects tissue without raising red blood cells. |
|---|---|---|
| Category | Recovery & Repair | Recovery & Repair |
| Evidence | 2/5No studies of the combination. Each part is mostly animal data with minimal human work. | 3/5Small human Phase 2 trials (sarcoidosis small-fiber neuropathy, type 2 diabetes neuropathy). No Phase 3. |
| FDA status | Not FDA-approved | Not FDA-approved |
| WADA (sport) | Banned | Banned |
| Also known as | Wolverine stack, BPC/TB blend | Cibinetide, Helix B surface peptide analog |
| How it works | BPC-157 appears to boost growth-factor signaling and new blood vessels at injury sites. TB-500 binds actin and helps cells move into damaged tissue. They act on different pathways, which is the rationale for pairing them. | Activates the 'innate repair receptor' (EPO receptor paired with the beta-common receptor), which calms inflammation and protects nerves. It does not activate the receptor that makes red blood cells, so it does not thicken blood the way EPO does. |
| Half-life | Short for both; dosed daily by convention | About 2 minutes in plasma; effects last much longer via receptor signaling |
| Commonly reported doses |
|
|
| Route | Subcutaneous | Subcutaneous |
| Good once mixed | ~28 days in the fridge | ~28 days in the fridge |
| Top side effects |
|
|
| Lowest research-listing price per mg | $4.50 (20 mg vial, 40% off) | $3.00 (10 mg vial, 40% off) |
| Latest lab purity | 99.52% (lot WLV0003) | 99.93% (lot ARA0002) |
Want a third? Add another peptide. Doses are commonly reported ranges, not recommendations.
Free for ChatGPT and Claude
Connect MyPeps to ChatGPT or Claude and ask follow-ups about BPC-157 + TB-500 and ARA-290. It answers from these same pages, with links back here.
BPC-157 + TB-500 is not FDA-approved and rated 2/5 for evidence; ARA-290 is not FDA-approved and rated 3/5. ARA-290 has more human evidence behind it. Both are banned in sport by WADA. Both are used for recovery & repair goals.
BPC-157 + TB-500: Not FDA-approved. ARA-290: Not FDA-approved. Regulations change, so confirm with the FDA.
BPC-157 + TB-500 is rated 2 out of 5: No studies of the combination. Each part is mostly animal data with minimal human work. ARA-290 is rated 3 out of 5: Small human Phase 2 trials (sarcoidosis small-fiber neuropathy, type 2 diabetes neuropathy). No Phase 3. The scale is explained on our methodology page.
BPC-157 + TB-500 is banned by WADA, by name or as part of a named class. ARA-290 is banned by WADA, by name or as part of a named class.